Published in Nature on June 25, 1966
Selective blockade of adrenoceptive beta receptors in the heart. Br J Pharmacol Chemother (1968) 14.80
Comparison of the effects of I.C.I. 50172 and propranolol on the cardiovascular responses to adrenaline, isoprenaline and exercise. Br J Pharmacol (1968) 4.20
Effects of adrenaline on human blood platelets. J Physiol (1967) 2.38
The peripheral vascular effects of propranolol and related compounds. Br J Pharmacol Chemother (1967) 1.87
A comparison of the anti-arrhythmic actions of I.C.I. 50172 and (--)-propranolol and their effects on intracellular cardiac action potentials and other features of cardiac function. Br J Pharmacol (1969) 1.57
The effect of adrenaline on the contraction of human muscle. J Physiol (1970) 1.52
A comparison of some cardiovascular properties of propranolol, MJ 1999 and quinidine in relation to their effects in hypertensive animals. Br J Pharmacol (1968) 1.29
Investigation of the mechanism of propranolol-induced bronchoconstriction. Br J Pharmacol (1979) 1.27
Beta-adrenergic blockade and cardiac arrhythmias. Br Med J (1967) 1.21
Nature of the calcium dependent potassium leak induced by (+)-propranolol, and its possible relevance to the drug's antiarrhythmic effect. Br J Pharmacol (1972) 1.21
Phosphatidic acid as a second messenger in human polymorphonuclear leukocytes. Effects on activation of NADPH oxidase. J Clin Invest (1991) 1.10
The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias. Br J Pharmacol (1968) 1.01
The characteristics of inhibition of histamine release from human lung fragments by sodium cromoglycate, salbutamol and chlorpromazine. Br J Pharmacol (1983) 0.97
Propranolol-induced airway hyperreactivity in guinea-pigs. Br J Pharmacol (1983) 0.96
Factors affecting the cerebrovascular response to noradrenaline in the dog. Br J Pharmacol (1975) 0.93
[Prevention of coplications in th combination of suprarenin infiltration with halothane and barbiturate anesthesia]. Arch Klin Exp Ohren Nasen Kehlkopfheilkd (1970) 0.92
Comparative study of six -adrenoceptive antagonists on airway resistance and heart rate in the guinea-pig. Br J Pharmacol (1972) 0.91
Suppression of ventricular arrhythmias in man by d-propranolol independent of beta-adrenergic receptor blockade. J Clin Invest (1990) 0.90
The role of beta1- and beta2-adrenoceptors in the inhibition of gastric acid secretion in the dog. Br J Pharmacol (1978) 0.88
Action of beta-adrenoceptor antagonists on the response to isoprenaline in the oestrogen dominated rabbit uterus. Br J Pharmacol (1975) 0.87
Effects of the autonomic system on insulin release in response to exogenous glucose in weaned lambs. J Physiol (1982) 0.87
Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine. Br J Clin Pharmacol (2005) 0.84
Effect of receptor blocking drugs on the depletion of brain glycogen by amphetamine. Br J Pharmacol (1971) 0.84
Physiological role of endogenous amines in the modulation of ventricular automaticity in the guinea-pig. J Physiol (1980) 0.83
Beta-adrenoceptor antagonists: studies on behaviour (delayed differentiation) in the monkey (Macaca mulatta). Br J Pharmacol (1980) 0.83
Inhibition of adrenomedullary catecholamine release by propranolol isomers and clonidine involving mechanisms unrelated to adrenoceptors. Br J Pharmacol (1987) 0.81
Studies on the stereoisomers of beta-adrenoceptor antagonists in conscious A-V blocked dogs. Br J Pharmacol (1986) 0.79
Beta 2-adrenoceptor blockade is the basis of guinea-pig bronchial hyper-responsiveness to leukotriene C4 and other agonists. Br J Pharmacol (1983) 0.79
Physiological and psychological effects of ±-propranolol, +-propranolol and diazepam in induced anxiety. Br J Clin Pharmacol (1974) 0.78
The electrophysiologic effects of beta-adrenergic blockade and cardiac denervation. Bull N Y Acad Med (1967) 0.78
Comparison of the anti-hypertensive response to beta-adrenoceptor blocking drugs in intact and adrenal-demedullated spontaneously hypertensive rats. Br J Pharmacol (1980) 0.78
Haemodynamic effects of dextro-propranolol in acute myocardial infarction. Thorax (1970) 0.78
The effects of the propranolol enantiomers on the intracardiac electrophysiological activities of Langendorff perfused hearts. Basic Res Cardiol (1989) 0.78
The effect of propranolol on vascular responses to sympathetic nerve stimulation. Br J Pharmacol (1975) 0.77
Decrease in ionic permeability of the cell membrane in guinea-pig atrial tissue by treatment with antifibrillatory agents and hexobarbitone, determined by means of 86Rb. Br J Pharmacol (1969) 0.77
Anti-arrhythmic, local anaesthetic, and adrenergic blocking activity of some beta-receptor antagonists. Br J Pharmacol (1969) 0.77
Inhibition of lymphocyte capping and transformation by propranolol and related compounds. Br J Pharmacol (1981) 0.77
Digoxin-induced ventricular arrhythmias in the guinea pig heart in vivo: evidence for a role of endogenous catecholamines in the genesis of delayed afterdepolarizations and triggered activity. Heart Vessels (1995) 0.77
Curare-like effect of propranolol on rat extraocular muscles. Br J Pharmacol (1980) 0.76
Effects of (plus or minus)-propranolol, (plus or minus)-,(plus)-, and (minus)-alprenolol on unanaesthetized dogs with ventricular arrhythmias resulting from coronary artery ligation. Br J Pharmacol (1970) 0.75
Beta-adrenoceptor blockade and atrio-ventricular conduction in dogs. Role of intrinsic sympathomimetic activity. Br J Clin Pharmacol (1982) 0.75
The role of the sympathetic system in the control of insulin release in response to hyperglycaemia in conscious calves. J Physiol (1985) 0.75
Role of the sympathetic nervous system in daunomycin-induced arrhythmia in the monkey. Br J Pharmacol (1970) 0.75
Ventricular arrhythmias induced in monkeys by the inhalation of aerosol propellants. J Clin Invest (1971) 0.75
Screening procedures in volunteers and patients. Br J Clin Pharmacol (1976) 0.75
Selective blockade of adrenoceptive beta receptors in the heart. Br J Pharmacol Chemother (1968) 14.80
Comparison of some properties of pronethalol and propranolol. Br J Pharmacol Chemother (1965) 4.71
Comparison of the effects of I.C.I. 50172 and propranolol on the cardiovascular responses to adrenaline, isoprenaline and exercise. Br J Pharmacol (1968) 4.20
The pharmacology of beta sympathetic blockade. Am J Cardiol (1966) 3.96
Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker. Clin Pharmacol Ther (1976) 3.16
The cardio-toxicity of isoprenaline during hypoxia. Br J Pharmacol (1969) 2.94
The clinical pharmacology of mexiletine. Br J Clin Pharmacol (1978) 2.56
Controlled trial of propranolol in thyrotoxicosis. Lancet (1969) 2.54
The effect of propranolol on the cardiovascular responses to isoprenaline, adrenaline and noradrenaline in the anaesthetized dog. Br J Pharmacol Chemother (1966) 2.52
Cardio-selective beta-blockade. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol (1968) 2.33
The effect of Kö 1173, a new anticonvulsant agent on experimental cardiac arrhythmias. Br J Pharmacol (1972) 2.11
The clinical pharmacology of beta adrenergic blocking drugs. J R Coll Physicians Lond (1976) 1.94
National Poisons Information Services: report and comment 1980. Br Med J (Clin Res Ed) (1981) 1.91
Oral mexiletine in high-risk patients after myocardial infarction. Lancet (1981) 1.91
The peripheral vascular effects of propranolol and related compounds. Br J Pharmacol Chemother (1967) 1.87
The effect of experimental cardiac arrhythmias of a new anticonvulsant agent, Kö 1173, and its comparison with phenytoin and procainamide. Br J Pharmacol (1970) 1.81
Blood levels of practolol after oral and parenteral administration and their relationship to exercise heart rate. Clin Pharmacol Ther (1974) 1.81
Influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade. Clin Pharmacol Ther (1977) 1.77
Observations on the efficacy and pharmacokinetics of sotalol after oral administration. Eur J Clin Pharmacol (1976) 1.71
Mexiletine (Kö 1173) in the management of ventricular dysrhythmias. Lancet (1973) 1.68
Some pharmacological properties of a new adrenergic beta-receptor antagonist. Nature (1966) 1.66
Effects of the beta 2-adrenoceptor antagonist ICI 118,551 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man. Br J Clin Pharmacol (1985) 1.65
Propranolol and the utilization of radioiodine by the human thyroid gland. Acta Endocrinol (Copenh) (1969) 1.63
Effect of propranolol on arrhythmias following coronary artery occlusion in dogs. Cardiovasc Res (1967) 1.61
Neonatal thyrotoxicosis treated with propranolol. Arch Dis Child (1974) 1.59
Comparison of the activity and plasma levels of oxprenolol, slow release oxprenolol, long acting propranolol and sotalol. Eur J Clin Pharmacol (1980) 1.57
Comparison of the efficacy and pharmacokinetics of conventional propranolol and a long acting preparation of propranolol. Br J Clin Pharmacol (1980) 1.55
Stimulation of adrenergic beta-receptors by orciprenaline. Br Med J (1967) 1.52
Debendox and congenital malformations in Northern Ireland. Br Med J (1980) 1.46
Clinical pharmacology methodology: introduction. Br J Clin Pharmacol (1978) 1.39
Comparison of the effect of propranolol, lignocaine, and other drugs on normal and raised intraocular pressure in man. Am J Ophthalmol (1971) 1.37
Spectrophotofluorometric and gas-liquid chromatographic methods for the estimation of mexiletine (Kö 1173) in plasma and urine. J Pharm Pharmacol (1973) 1.36
Duration of action of beta-blocking drugs. Br Med J (1973) 1.33
Effects of alinidine, a novel bradycardic agent, on heart rate and blood pressure in man. J Cardiovasc Pharmacol (1982) 1.32
Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Br J Haematol (1995) 1.31
Propranolol and iodine-131 in the management of thyrotoxicosis. Lancet (1968) 1.29
Stimulation of gastrin release by catecholamines. Lancet (1972) 1.26
Microbiological oxidation of long-chain aliphatic compounds. I. Alkanes and alk-1-enes. J Chem Soc Perkin 1 (1968) 1.26
Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin. J Antimicrob Chemother (1995) 1.24
Comparison of the effects of propranolol and MJ 1999 on cardiac beta-adrenoceptors in man. Br J Pharmacol (1970) 1.24
Effects on exercise tachycardia during forty-eight hours of a series of doses of atenolol, sotalol, and metoprolol. Clin Pharmacol Ther (1981) 1.23
Effects of the myocardial-selective alpha 1-adrenoceptor antagonist UK-52046 and atenolol, alone and in combination, on experimental cardiac arrhythmias in dogs. Br J Pharmacol (1988) 1.17
Cardiovascular effects of alinidine and propranolol alone and in combination with hydralazine in normal man. Br J Clin Pharmacol (1983) 1.16
Effects on sleep disturbance of changes in aircraft noise near three airports. J Acoust Soc Am (2000) 1.15
Correlation of reduction of exercise heart rate with blood levels of atenolol after oral and intravenous administration. Postgrad Med J (1977) 1.13
Blood cell abnormalities complicating the hypophosphatemia of hyperalimentation: erythrocyte and platelet ATP deficiency associated with hemolytic anemia and bleeding in hyperalimented dogs. J Lab Clin Med (1974) 1.12
ICI D7114 a novel selective beta-adrenoceptor agonist selectively stimulates brown fat and increases whole-body oxygen consumption. Br J Pharmacol (1991) 1.12
Effects of aircraft overflights on wilderness recreationists. J Acoust Soc Am (1996) 1.12
Is verapamil a beta-blocker? Lancet (1968) 1.11
The role of the thyroid in the control of heart-rate. Lancet (1968) 1.10
The development of mexiletine in the management of ventricular dysrhythmias. Postgrad Med J (1977) 1.09
The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Cancer Chemother Pharmacol (1982) 1.08
Natural and acquired resistance to Leishmania: cellular activation by Leishmania aethiopica of mononuclear cells from unexposed individuals is through the stimulation of natural killer (NK) cells. Clin Exp Immunol (1993) 1.07
Alinidine reduces heart-rate without blockade of beta-adrenoceptors. Lancet (1981) 1.06
Differential gene expression of activating Fcγ receptor classifies active tuberculosis regardless of human immunodeficiency virus status or ethnicity. Clin Microbiol Infect (2013) 1.04
Effects of lignocaine and propranolol on experimental cardiac arrhythmias. Br J Pharmacol (1971) 1.04
Characterization of the beta-adrenoreceptors which mediate the isoprenaline-induced changes in finger tremor and cardiovascular function in man. Eur J Clin Pharmacol (1988) 1.03
Effects of ICI 141,292 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man. Br J Clin Pharmacol (1986) 1.01
The effect of the dextro isomer of propranolol on sinus rate and cardiac arrhythmias. Am Heart J (1968) 1.01
The selectivity of xamoterol, prenalterol, and salbutamol as assessed by their effects in the presence and absence of ICI 118,551. J Cardiovasc Pharmacol (1988) 1.00
Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug. Br J Clin Pharmacol (1981) 1.00
Comparison of the effects of isoprenaline, orciprenaline, salbutamol and isoetharine on the cardiovascular system of anaesthetized dogs. Br J Pharmacol (1971) 1.00
The properties of beta-adrenoceptor antagonists. Postgrad Med J (1976) 1.00
Suppression of ventricular arrhythmias after coronary artery ligation by pinacidil, a vasodilator drug. J Cardiovasc Pharmacol (1985) 0.98
A comparison of the cardiovascular actions of four adrenergic -receptor blocking agents in resting, conscious dogs. Am Heart J (1971) 0.97
Mexiletine in normal volunteers. Br J Clin Pharmacol (1978) 0.97
Metabolism of 2-(4-chlorophenyl)thiazol-4-ylacetic acid (fenclozic acid) and related compounds by microorganisms. J Med Chem (1972) 0.96
Comparison of the duration of effect of metoprolol and a sustained release formulation of metoprolol (betaloc-SA). Br J Clin Pharmacol (1981) 0.96
Pharmacokinetics of low-dose methotrexate in children receiving maintenance therapy for acute lymphoblastic leukaemia. Cancer Chemother Pharmacol (1982) 0.94
Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update. Clin Pharmacokinet (1987) 0.90
Inhibition of the carotid sinus reflex by the chronic administration of propranolol. Br J Pharmacol (1969) 0.89
Cell-mediated immunity in trachomatous scarring. Evidence from a leprosy population. Ophthalmology (1993) 0.89
Studies of the agonist and antagonist activity of cicloprolol in man. Eur J Clin Pharmacol (1988) 0.89
Celiprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in hypertension and angina pectoris. Drugs (1987) 0.89
Managing uncertainty in environmental decisions. Environ Sci Technol (2001) 0.88
Changes in heart rate and forearm blood flow following intravenous boluses of isoprenaline in the presence of practolol and propranolol. Br J Clin Pharmacol (1983) 0.88
Slow release beta-adrenoceptor blocking drugs. J R Coll Physicians Lond (1983) 0.88
Glutamate-immunoreactivity in the trigeminal and dorsal root ganglia, and intraspinal neurons and fibres in the dorsal horn of the rat. Histochem J (1991) 0.88
A comparison of statistical methods for low dose extrapolation utilizing time-to-tumor data. Fundam Appl Toxicol (1983) 0.88
A comparison of the cardioselectivity of five beta-adrenoceptor blocking drugs. J Cardiovasc Pharmacol (1987) 0.87
Alinidine pharmacokinetics following acute and chronic dosing. Br J Clin Pharmacol (1982) 0.87
Investigation into mechanism of lack of reflex tachycardia in response to hypotensive action of indoramin in dogs. J Cardiovasc Pharmacol (1984) 0.87
Further observations on the cardiotoxicity of isoprenaline during hypoxia. Br J Pharmacol (1974) 0.87
Modern lineages of Mycobacterium tuberculosis in Addis Ababa, Ethiopia: implications for the tuberculosis control programe. Afr Health Sci (2012) 0.86
Cardiovascular effects of indoramin in man--a dose ranging study. Br J Clin Pharmacol (1983) 0.86
Differential blockade of alpha-adrenoceptors by indoramin. Br J Clin Pharmacol (1984) 0.86
Can severe vincristine neurotoxicity be prevented? Cancer Chemother Pharmacol (1982) 0.86
ICI D7114: a novel selective adrenoceptor agonist of brown fat and thermogenesis. Am J Clin Nutr (1992) 0.86
Carcinogenicity of "Alderlin" (pronethalol) in mice. Nature (1965) 0.86
Effects of viloxazine, its optical isomers and its major metabolites on biogenic amine uptake mechanisms in vitro and in vivo. Eur J Pharmacol (1978) 0.85
Effect of very early intervention with metoprolol on myocardial infarct size. Br Heart J (1983) 0.85
A comparative pharmacokinetic study of conventional propranolol and long acting preparation of propranolol in patients with cirrhosis and normal controls. Br J Clin Pharmacol (1987) 0.84
Evaluation of once daily sotalol administration in man. Br J Clin Pharmacol (1977) 0.84
Hyperalimentation hypophosphatemia: hematologic-neurologic dysfunction due to ATP depletion. Trans Assoc Am Physicians (1973) 0.84
Beta-adrenergic blocking agents. I. Pronethalol and related N-alkyl and N-aralkyl derivatives of 2-amino-1-(2-naphythyl)ethanol. J Med Chem (1968) 0.84
Effects of betaxolol, propranolol, and atenolol on isoproterenol-induced beta-adrenoceptor responses. Clin Pharmacol Ther (1985) 0.84
Acute haemodynamic effects of pinacidil in man. Br J Clin Pharmacol (1986) 0.84
Microbiological reduction of 2-methyl-1,2-di-3-pyridyl-1-propanone (metyrapone). J Med Chem (1971) 0.84
Human pharmacokinetic and pharmacodynamic studies on Ro31-1118, a new beta-adrenoceptor antagonist. Br J Clin Pharmacol (1985) 0.83
Effects of azepexole and clonidine on baroreceptor mediated reflex bradycardia and physiological tremor in man. Br J Clin Pharmacol (1985) 0.83